6/9/25 We are currently making changes to reflect the new Health Sciences Division structure. Thank you for your patience while we make the transition.

Sign in
Back
First trimester exposure to smoking cessation pharmacotherapies and the risk of major congenital malformations: A multi-national cohort study
Conference paper   Peer reviewed

First trimester exposure to smoking cessation pharmacotherapies and the risk of major congenital malformations: A multi-national cohort study

Duong T. Tran, Carolyn E. Cesta, Jacqueline M. Cohen, Sarah Michelle Donald, Kari Furu, Erin Kelty, Lianne Ruth Parkin, Sallie-Anne Pearson, Johan Reutfors, Annelies L. Robijn, …
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol.32, pp.539-539
International Conference on Pharmacoepidemiology and Therapeutic Risk Management, 39 (Halifax, Canada, 25/08/2023–27/08/2023)
Wiley
01/10/2023
DOI: https://doi.org/10.1002/pds.5687
Handle:
https://hdl.handle.net/10523/17785

Abstract

Life Sciences & Biomedicine Pharmacology & Pharmacy Public, Environmental & Occupational Health Science & Technology
Background: The pharmacotherapies varenicline, bupropion and nico-tine replacement therapy (NRT) are the most effective strategies forsmoking cessation. Prior studies of these medicines in pregnancy havenot been adequately powered to generate clear evidence on the riskof congenital malformations.Objectives: To assess the risk of major congenital malformations(MCM) associated with exposure to varenicline, NRT and bupropion(for smoking cessation) in the first trimester.

Metrics

17 Record Views

Details

Logo image